Is Viking Therapeutics Stock Going to $100?

Shares of Viking Therapeutics (NASDAQ: VKTX) have climbed by 27% over the past month. The drugmaker is a serious candidate to make waves in the large and growing anti-obesity drug market. With several ongoing clinical trials, there could be important catalysts on the horizon. Viking's shares are currently trading at about $40 apiece. Could the stock soar over the next 18 months and reach $100?Image source: The Motley Fool.Viking Therapeutics' leading weight-loss candidate, VK2735, mimics the actions of two gut hormones, GLP-1 and GIP. The former helps control satiety, while the latter helps regulate blood glucose. Medicines that activate both pathways could deliver better weight loss than those that only mimic the GLP-1 hormone, as we have seen with Zepbound, a dual GLP-1 and GIP agonist that is currently the best-selling weight management drug. Viking Therapeutics' VK2735 is undergoing a pair of phase 3 studies in overweight or obese patients.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool